Retatrutide: The Triple Receptor Agonist That May Surpass Semaglutide and Tirzepatide

What Is Retatrutide?

Retatrutide is a single synthetic peptide that binds to three separate hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. No other approved obesity drug targets all three simultaneously. Developed by Eli Lilly, it is administered as a once-weekly subcutaneous injection. Phase 2 data published in the New England Journal of Medicine in 2023 showed that the 12 mg dose produced a mean 24.2% reduction in body weight at 48 weeks in adults with obesity, which is numerically larger than anything reported for a single agent in a controlled trial to that point.

The GLP-1 component slows gastric emptying and reduces appetite through central nervous system signaling. The GIP component may amplify insulin secretion and improve GLP-1 receptor sensitivity. The glucagon component is the distinguishing addition: glucagon receptor activation increases energy expenditure and promotes hepatic fat mobilization. This third mechanism is theorized to account for retatrutide's edge over dual agonists like tirzepatide in preclinical and early human data, though the exact contribution in humans is still being quantified in ongoing Phase 3 studies.

Retatrutide is not approved by the FDA for any indication as of January 2025. Patients who ask about it should understand that access currently requires enrollment in a clinical trial or compassionate-use application.

How Retatrutide Works: Triple Agonism Explained

Activating three receptors at once produces overlapping and potentially additive metabolic effects. Each pathway does something distinct.

GLP-1 receptor agonism reduces appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. This is the same mechanism that makes semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) effective for both weight loss and glycemic control. Semaglutide is a highly selective GLP-1 agonist; STEP-1 (N=1,961) reported a mean 14.9% body weight reduction at 68 weeks with 2.4 mg once weekly versus 2.4% with placebo [1].

GIP receptor agonism, the second target, is shared with tirzepatide (Mounjaro, Zepbound). SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks, compared to 3.1% for placebo [2]. The GIP receptor may work partly by reducing the nausea associated with pure GLP-1 stimulation, which could allow higher effective dosing.

Glucagon receptor agonism is the element that separates retatrutide from every approved agent. Glucagon historically raises blood glucose, which is why its role in an anti-obesity drug seems counterintuitive. At the doses used in retatrutide, however, the net metabolic effect in combination with GLP-1 and GIP co-activation appears to increase basal energy expenditure and accelerate lipolysis, particularly visceral fat. Animal models and the Phase 2 human trial both showed meaningful reductions in liver fat, a finding relevant for patients with metabolic-associated steatotic liver disease (MASLD).

Retatrutide Phase 2 Trial: What the Data Actually Show

The key Phase 2 study of retatrutide enrolled 338 adults with a BMI of 30 or higher (or BMI <30 with at least one weight-related comorbidity) and no type 2 diabetes. Participants were randomized to placebo or one of five active doses: 1 mg, 4 mg, 8 mg, or 12 mg once weekly, with two titration schedules for the 8 mg group. The primary endpoint was percentage change in body weight at 24 weeks; 48-week outcomes were the key secondary [3].

Results at 48 weeks by dose arm:

• 1 mg: mean weight loss approximately 8.7%
• 4 mg: mean weight loss approximately 17.3%
• 8 mg (standard titration): mean weight loss approximately 22.8%
• 12 mg: mean weight loss approximately 24.2%
• Placebo: mean weight loss approximately 2.1%

All active doses produced statistically significant weight loss versus placebo (P<0.001 for the 8 mg and 12 mg arms). At 48 weeks, 26% of participants on 12 mg had lost 30% or more of body weight. No approved single agent has produced a 30% responder rate of that magnitude in a controlled trial.

The 68-week projection of 28.7% comes from a separate analysis modeling the trajectory of weight loss in the 12 mg cohort beyond 48 weeks, using the curve at week 48, which had not yet plateaued. This number should be interpreted with caution: it is modeled, not directly observed, and Phase 3 data will be the true test.

Cardiometabolic markers also improved. Waist circumference decreased by a mean of 23.4 cm in the 12 mg arm. Systolic blood pressure fell by about 7.2 mmHg. Triglycerides dropped roughly 40%. Liver fat fraction, measured by MRI-PDFF in a subgroup, decreased substantially, supporting a potential role in MASLD management.

Retatrutide vs. Semaglutide: A Direct Comparison

Semaglutide (Wegovy) is the current FDA-approved standard for pharmacologic weight management in most obesity medicine practices. The comparison with retatrutide is numerically striking but requires careful framing.

STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo [1]. STEP-3 (N=611) tested semaglutide combined with intensive behavioral therapy and found a 16.0% mean weight reduction at 68 weeks [4]. STEP-5 followed participants for 104 weeks and reported sustained 15.2% mean weight loss, showing durability of effect [5]. The SELECT trial (N=17,604) added a cardiovascular dimension: semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease, over a mean follow-up of 34.2 months [6].

The FDA approved the Wegovy label for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related condition [7].

Retatrutide's Phase 2 12 mg arm produced 24.2% at 48 weeks, which is roughly 9 percentage points more than semaglutide's 68-week result. The trials are not head-to-head, the populations differ slightly, and 48 weeks is shorter than 68 weeks. However, the retatrutide weight loss curve had not plateaued at 48 weeks, suggesting continued loss beyond that timepoint.

Semaglutide has several practical advantages right now: FDA approval, an established cardiovascular outcomes trial, long-term safety data extending past two years, and a once-weekly pill formulation (Rybelsus) for patients who prefer oral administration. Retatrutide currently has none of those.

For glycemic control in type 2 diabetes, STEP-2 (N=1,210) found semaglutide 2.4 mg reduced HbA1c by 1.6 percentage points versus 0.4 for placebo at 68 weeks [8]. Retatrutide Phase 2 also enrolled a separate cohort with type 2 diabetes; results showed HbA1c reductions up to 2.02 percentage points with 12 mg [3], modestly exceeding the semaglutide result, though again the trials are not directly comparable.

Retatrutide vs. Tirzepatide: How Close Is the Gap?

Tirzepatide (Zepbound for obesity, Mounjaro for T2D) is the most effective approved weight-loss drug currently on the market. SURMOUNT-1 (N=2,539) showed 20.9% mean weight loss at 72 weeks with the 15 mg dose [2]. SURMOUNT-3 (N=579) tested tirzepatide after a 12-week lead-in with intensive lifestyle intervention and found 18.4% additional weight loss on drug after the lifestyle run-in, for a combined total of 24.3% from baseline [9]. SURMOUNT-4 demonstrated that stopping tirzepatide led to regain of 14 percentage points of body weight over 52 weeks versus ongoing treatment [10].

The Zepbound FDA label approves tirzepatide for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity [11].

Retatrutide's 12 mg arm at 48 weeks (24.2%) numerically exceeds tirzepatide's 15 mg arm at 72 weeks (20.9%) despite being measured at a shorter timepoint. The modeled 68-week estimate of 28.7% extends that gap further. The Phase 2 study directly referenced the SURMOUNT-1 comparator when discussing clinical meaning.

Key differences between the two molecules: tirzepatide does not activate glucagon receptors. That third target in retatrutide may account for the additional weight loss through increased energy expenditure, but it also raises a theoretical concern. Sustained glucagon receptor activation can raise fasting glucose. In the Phase 2 trial, fasting glucose increased transiently in some participants, more so at 8 mg and 12 mg, though GLP-1 and GIP co-activation appeared to offset most of this effect. Phase 3 data with longer follow-up will clarify the long-term glycemic profile.

The HealthRX clinical decision framework below provides a practical comparison of all four agents for a prescribing clinician's use during patient counseling. It is intended to be replaced with a custom-illustrated figure during editorial review.

Receptor-target and efficacy comparison: GLP-1 class agents

| Agent | GLP-1 | GIP | Glucagon | Approval | Best trial weight loss | |---|---|---|---|---|---| | Liraglutide (Saxenda) | Yes | No | No | FDA-approved | 8.0% at 56 weeks (SCALE) | | Dulaglutide (Trulicity) | Yes | No | No | T2D only | 3.0 kg mean at 52 weeks | | Semaglutide (Wegovy) | Yes | No | No | FDA-approved | 14.9% at 68 weeks (STEP-1) | | Tirzepatide (Zepbound) | Yes | Yes | No | FDA-approved | 20.9% at 72 weeks (SURMOUNT-1) | | Retatrutide | Yes | Yes | Yes | Investigational | 24.2% at 48 weeks (Phase 2) |

Liraglutide and Dulaglutide: Where They Fit Now

Liraglutide (Saxenda, 3 mg once daily subcutaneous) was the first GLP-1 agonist approved specifically for obesity in the United States. The SCALE Obesity and Prediabetes trial (N=3,731) showed a mean 8.0% weight loss at 56 weeks versus 2.6% for placebo, with 63.2% of participants achieving ≥5% weight loss [12]. STEP-8 compared semaglutide 2.4 mg once weekly head-to-head against liraglutide 3 mg once daily in 338 adults with obesity. Semaglutide produced 15.8% mean weight loss versus 6.4% for liraglutide at 68 weeks, a difference of 9.4 percentage points [13].

The guideline from the American Association of Clinical Endocrinology (AACE/ACE) recommends GLP-1 receptor agonists as preferred pharmacologic agents for obesity with metabolic comorbidities, with preference for agents showing the greatest efficacy and tolerability in the individual patient [14].

Liraglutide's daily injection schedule and comparatively modest weight loss make it a second-line choice in most current obesity medicine practices, reserved for patients who cannot tolerate once-weekly formulations or who have insurance constraints. Saxenda costs approximately $1,349 per month without insurance in the United States.

Dulaglutide (Trulicity) is a once-weekly GLP-1 agonist approved for type 2 diabetes management. It is not FDA-approved for obesity or chronic weight management. The AWARD-11 trial (N=1,842) showed the 4.5 mg dose reduced HbA1c by 1.77 percentage points versus 1.36 for 1.5 mg at 52 weeks [15]. Weight loss in dulaglutide trials is typically 3 to 4 kg, substantially less than semaglutide or tirzepatide. Dulaglutide's REWIND cardiovascular outcomes trial (N=9,901) did show a 12% reduction in major adverse cardiovascular events versus placebo over 5.4 years, which supports its use in patients with T2D and cardiovascular risk. Dulaglutide has no role in obesity-first prescribing under current guidelines.

Side Effects and Safety Profile Across the GLP-1 Class

The GLP-1 receptor agonist class shares a consistent side-effect profile dominated by gastrointestinal symptoms. Nausea affects approximately 40 to 44% of patients on semaglutide 2.4 mg in STEP-1, versus 16% on placebo [1]. Vomiting, diarrhea, and constipation occur in 20 to 30% of active-drug participants. Most symptoms peak during dose escalation and decrease at maintenance dosing.

Tirzepatide shows comparable gastrointestinal rates. In SURMOUNT-1, nausea affected 33% of participants on the 15 mg dose versus 9% on placebo [2]. Slower titration schedules reduce discontinuation rates.

Retatrutide's Phase 2 trial reported nausea in approximately 45 to 58% of participants at the 8 mg and 12 mg doses, with vomiting in 20 to 30%. Discontinuation due to adverse events was 16% in the 12 mg arm, higher than the roughly 7% discontinuation rate reported in SURMOUNT-1 for the highest tirzepatide dose [2]. This tolerability gap may shrink with the optimized titration schedules being tested in Phase 3, but it represents a real limitation of the current Phase 2 protocol.

Serious risks across the class include pancreatitis (rare; estimated at 0.1 to 0.2 per 100 patient-years), gallbladder disease, and a theoretical concern about medullary thyroid carcinoma (based on rodent studies; observed with liraglutide and semaglutide in animal models, not confirmed in human epidemiology to date). The Wegovy FDA label carries a black-box warning for MTC risk in patients with a personal or family history of MTC or MEN2 [7].

Retatrutide's glucagon component introduces an additional monitoring consideration: transient increases in fasting plasma glucose have been observed, particularly during dose escalation at 12 mg. In the Phase 2 T2D cohort, this was offset by GLP-1/GIP-mediated insulin secretion, but close monitoring of fasting glucose during titration seems warranted.

Current Access and What Patients Should Know

Retatrutide has no approved route to prescription as of January 2025. There are three practical pathways:

1. Clinical trial enrollment. The Phase 3 TRIUMPH program includes multiple trials studying retatrutide in adults with obesity, with and without type 2 diabetes, and a dedicated cardiovascular outcomes trial. ClinicalTrials.gov lists active sites in the United States as of late 2024.

2. Expanded access (compassionate use). Eli Lilly has not publicly announced an expanded-access program for retatrutide. Prescribers can submit individual patient requests to FDA under 21 CFR 312.310, but approval is not guaranteed and supply may be unavailable.

3. Compounded versions. Some compounding pharmacies have begun offering peptides marketed as "retatrutide." These products are not FDA-reviewed, not manufactured to pharmaceutical GMP standards, and do not have documented safety or efficacy data. HealthRX does not prescribe compounded retatrutide.

For patients who need the most effective currently-approved agent, tirzepatide 15 mg remains the benchmark. SURMOUNT-4 showed that stopping tirzepatide leads to regain, so plans for long-term therapy are necessary before starting [10].

Retatrutide's Phase 3 Program and Expected Timeline

Eli Lilly launched the TRIUMPH Phase 3 program in 2023 and 2024. Key trials include TRIUMPH-1 (obesity without diabetes, primary weight loss endpoint at 72 weeks), TRIUMPH-2 (obesity with type 2 diabetes), and TRIUMPH-CVOT (cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease, mirroring the SELECT trial design).

Assuming Phase 3 results are positive and an NDA is filed, FDA review typically takes 6 to 12 months under standard review or 6 months under priority review designation. An optimistic timeline places a potential approval in late 2026 or 2027. This is speculative; Phase 3 trials can fail, and regulatory timelines extend.

The cardiovascular outcomes data will be essential for positioning retatrutide against semaglutide. SELECT showed semaglutide reduced MACE by 20% in a high-risk population [6]. If TRIUMPH-CVOT shows a comparable or superior reduction, that would address the primary remaining gap in retatrutide's clinical profile versus semaglutide.

The American Association of Clinical Endocrinology notes that "the selection of anti-obesity pharmacotherapy should be individualized based on efficacy, safety, tolerability, cost, and patient preference" [14]. Retatrutide will need to demonstrate durability, safety over at least two years, and a tolerable discontinuation rate before it can displace tirzepatide as the top-line agent for most patients.